What is Axsome Therapeutics, Inc.'s current stock price?

Axsome Therapeutics, Inc. (AXSM) currently trades at USD 168.51. Track real-time price changes and historical performance on AllInvestView.

What sector is Axsome Therapeutics, Inc. in?

Axsome Therapeutics, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Axsome Therapeutics, Inc. AXSM Open Axsome Therapeutics, Inc. in new tab

168.51 USD

EPS

-3.67

P/B

97.12

ROE

-252.12

Beta

0.47

Target Price

223.66 USD

Axsome Therapeutics, Inc.

🧾 Earnings Recap – Q3 2025

Axsome Therapeutics reported robust Q3 2025 results, with total revenue rising 63% year-over-year to $171 million, driven by strong demand for AUVELITY and steady growth of SUNOSI.

AUVELITY sales reached $136.1 million, a 69% increase year-over-year, reflecting strong market traction.
SUNOSI revenues grew 35% year-over-year to $32.8 million, demonstrating ongoing commercial momentum.
Axsome submitted a supplemental NDA for AXS-05 in Alzheimer's disease agitation and plans to initiate multiple Phase III trials across ADHD and narcolepsy.
The company is well-positioned with a deep late-stage pipeline and a diverse portfolio of therapies addressing significant unmet needs in CNS health.

View full recap page

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Axsome Therapeutics, Inc. (AXSM)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Axsome Therapeutics, Inc. Analysis (AXSM)

United States Health Care Official Website Stock

Is Axsome Therapeutics, Inc. a good investment? Axsome Therapeutics, Inc. (AXSM) is currently trading at 168.51 USD. Market analysts have a consensus price target of 223.66 USD. This suggests a potential upside from current levels.

Earnings Schedule: Axsome Therapeutics, Inc. is expected to release its next earnings report on May 11, 2026. The market consensus estimate for Forward EPS is 6.08.

Investor FAQ

Does Axsome Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Axsome Therapeutics, Inc.?

Axsome Therapeutics, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 11, 2026. The company currently has a trailing EPS of -3.67.

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Exchange Ticker

NMS (United States) AXSM

LSE (United Kingdom) 0HKF.L

FRA (Germany) 19X.F

STU (Germany) 19X.SG

No dividends available.

Dividends

Historical Split Corporate Actions

No corporate actions available.

Trades

Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Community Discussion

Twitter YouTube Reddit Feature Requests Support Pricing Help

Support email: support@allinvestview.com

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.

Axsome Therapeutics, Inc. AXSM Open Axsome Therapeutics, Inc. in new tab

Axsome Therapeutics, Inc.

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Axsome Therapeutics, Inc. Analysis (AXSM)

Investor FAQ

Company Profile

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

Axsome Therapeutics, Inc. AXSM Open Axsome Therapeutics, Inc. in new tab

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Axsome Therapeutics, Inc. Analysis (AXSM)

Investor FAQ

Company Profile

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

Notifications